Intralesional IL-2 Promising for Cutaneous Melanoma Metastases

This article originally appeared here.
Share this content:
Intralesional IL-2 Promising for Cutaneous Melanoma Metastases
Intralesional IL-2 Promising for Cutaneous Melanoma Metastases

WEDNESDAY, Sept. 23, 2015 (HealthDay News) -- Patients with cutaneous melanoma metastases have excellent response to intralesional interleukin 2 (IL-2) administered concomitantly with topical imiquimod and a retinoid cream, according to a case series published in the October issue of the Journal of the American Academy of Dermatology.

Vivian Y. Shi, M.D., from the University of California in Davis, and colleagues examined the effectiveness of intralesional IL-2 combined with topical imiquimod and a retinoid cream in a retrospective case series of 11 patients with cutaneous metastatic melanoma.

The researchers found that for all 11 patients treated with this proposed regimen there was a 100 percent complete local response rate with long-term follow-up (average of 24 months). Absence of malignant cells was confirmed with biopsy specimens of treated sites. Rigors was the most common treatment-related adverse event.

"Intralesional IL-2 administered concomitantly with topical imiquimod and a retinoid cream is a promising therapeutic option for managing cutaneous melanoma metastases," the authors write. "The regimen was well tolerated and should be considered as a reasonable alternative to surgical excision."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Congress Approves Bill Expanding Private Care for VA Patients

Congress Approves Bill Expanding Private Care for VA ...

New bill would open up access to private doctors for veterans

AAP Recommending Injectable Flu Shot for 2018-19 Flu Season

AAP Recommending Injectable Flu Shot for 2018-19 Flu ...

Children should receive injectable vaccine, which has been shown to be more consistently effective

Neurologists Identify New Type of Vertigo

Neurologists Identify New Type of Vertigo

Long-term prognosis favorable, with improvement of symptoms in more than half of patients